Date: 15 Nov 2012
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Mometasone, a synthetic 16α-methyl analogue of beclomethasone, is classified as a ‘potent’ glucocorticoid for dermatological use. It is available as 0.1% cream, ointment and lotion formulations for the treatment of patients with inflammatory glucocorticoid-responsive dermatoses.
In patients with atopic dermatitis, the effects of mometasone 0.1% applied once daily over 2 to 3 weeks were similar to those of other glucocorticoids of similar potency, such as betamethasone dipropionate 0.05% twice daily and methylprednisolone aceponate 0.1% once daily. Mometasone 0.1% was significantly superior to twice-daily application of less potent glucocorticoids such as clobetasone 0.05%, hydrocortisone 1.0%, hydrocortisone butyrate and hydrocortisone valerate 0.2%. In patients with seborrhoeic dermatitis, mometasone 0.1% was more effective than ketoconazole 2.0% and hydrocortisone 1.0% in trials lasting 4 or 6 weeks. In the management of scalp psoriasis and psoriasis vulgaris, mometasone 0.1% applied once daily for 2 to 8 weeks was generally more effective than other glucocorticoids of similar or weaker potency such as betamethasone valerate 0.1%, fluocinolone acetonide 0.025%, fluticasone propionate 0.005%, triamcinolone acetonide 0.1% and hydrocortisone 1.0% and as effective as diflucortolone valerate 0.1%. Alternate day application of mometasone 0.1% for 2 weeks was as effective as once-daily application in maintaining symptom control in a small number of patients with psoriasis vulgaris.
Although mometasone demonstrates greater anti-inflammatory activity and a longer duration of action than betamethasone, it has low potential to cause adverse systemic effects such as suppression of the hypothalamic-pituitary-adrenal (HPA) axis. Moreover, its atrophogenic potential is low and no greater than that of other glucocorticoids in its class, such as betamethasone valerate. Transient, mild to moderate, local adverse effects such as burning, stinging, folliculitis, dryness, acneiform eruptions and signs of skin atrophy have been reported with mometasone. Mometasone has shown a low risk of primary sensitisation and cross-reactions in preliminary patch test studies.
Mometasone is a well tolerated topical glucocorticoid effective in the management of patients with atopic dermatitis, seborrhoeic dermatitis, scalp psoriasis and psoriasis vulgaris. In addition to its low potential for causing primary sensitisation and cross-reactions with other topical glucocorticoids, mometasone offers the convenience of once-daily administration.
Mometasone has high lipophilicity and displays greater in vitro affinity for glucocorticoid receptors in rat epidermis than betamethasone dipropionate. In suppressing erythema induced by ultraviolet (UV)-B light, mometasone showed greater activity and a longer duration of action than betamethasone dipropionate and betamethasone valerate. However, it showed little potential to suppress the hypothalamic-pituitary-adrenal axis in patients and healthy volunteers.
An in vitro study on human fibroblasts and keratinocytes reported the anti-proliferative effects of mometasone to be negligible or small compared with those of betamethasone valerate. No clinical or histological signs of skin atrophy were observed in 6 volunteers after 12 months of once-daily application of mometasone 0.1% cream. Some clinical trials have found the atrophogenic potential of mometasone to be low and similar to that of hydrocortisone, prednicarbate, betamethasone valerate and methylprednisolone aceponate. However, in one trial, mometasone 0.1% ointment was associated with a significantly greater incidence and severity of skin atrophy and telangiectasia than methylprednisolone aceponate 0.1% ointment.
Little topically applied mometasone reaches the systemic circulation. In human volunteers, only 0.7% of mometasone 0.1% ointment was systemically absorbed after a contact time of 8 hours without occlusive dressing. After application of 10g 0.1% ointment under occlusion, the plasma concentration of mometasone peaked at about 130 ng/L in 12 hours and then declined rapidly.
Atopic dermatitis. In short term studies (≤6 weeks) once-daily mometasone 0.1% cream or ointment was significantly more effective in reducing total sign and symptom severity scores than twice-daily clobetasone 0.05% ointment, clobetasone 0.05% cream, hydrocortisone butyrate cream, hydrocortisone valerate 0.2% cream and hydrocortisone 1.0% cream and as effective as once-daily methylprednisolone aceponate 0.1% cream or twice-daily betamethasone dipropionate 0.05% ointment in the treatment of moderate to severe atopic dermatitis.
Seborrhoeic dermatitis. Once-daily application of mometasone 0.1% solution was more effective and showed a faster onset of action than ketoconazole 2.0% shampoo applied twice weekly over 4 weeks in the treatment of patients with moderate to severe seborrhoeic dermatitis. Significantly greater improvement was observed after 6 weeks with mometasone 0.1% cream applied once daily than with hydrocortisone 1.0% cream applied twice daily. Psoriasis. Mometasone 0.1% lotion or ointment applied once daily was significantly more effective than twice-daily betamethasone valerate 0.1% lotion or ointment over 2 to 8 weeks in 3 trials in patients with scalp psoriasis or psoriasis vulgaris. The once-daily application of mometasone 0.1% cream, lotion or ointment formulations produced significantly greater reductions in total psoriatic symptom scores than once-daily hydrocortisone 1% ointment, twice-daily fluticasone propionate 0.005% ointment, triamcinolone acetonide 0.1% lotion or ointment or 3-times-daily fluocinolone acetonide 0.025% cream or ointment. In patients with psoriasis vulgaris, mometasone applied once daily was as effective as twice-daily diflucortolone valerate 0.1% ointment and triamcinolone acetonide 0.1% cream. Results of a preliminary short term study suggest that application of mometasone 0.1% ointment on alternate days may be as effective as once-daily application in maintenance therapy in patients with psoriasis vulgaris.
Topical mometasone 0.1% cream was associated with local cutaneous adverse effects in 1.6 and 7.0% of 319 adult and 74 paediatric patients, respectively. The most commonly encountered adverse effects included stinging, burning, pruritus, folliculitis, dryness, acneiform/erythematous eruptions, tenderness and signs of skin atrophy. These adverse effects were transient and of mild or mild to moderate intensity.
Preliminary patch test studies have reported that the risk of primary sensitisation or cross-reaction with mometasone is low, even in patients known to be hypersensitive to glucocorticoids.
Dosage and Administration
Mometasone 0.1% cream, ointment or lotion is indicated for the symptomatic relief of inflammation and pruritus in patients with glucocorticoid-responsive dermatoses. It should be applied without occlusion to the affected areas once daily. Like other topical glucocorticoids, mometasone should not be used in patients with primary cutaneous viral, bacterial or fungal infections, rosacea, acne, perioral dermatitis, or perianal or genital pruritus. It may be used with caution in children aged ≥2 years.
Various sections of the manuscript reviewed by: A. Goossens, Department of Dermatology, Katholieke Universiteit, Leuven, Belgium; B. Homey, Department of Dermatology, Heinrich Heine University, Dusseldorf, Germany; V. Koivukangas, Department of Dermatology, University of Oulu, Oulu, Finland; A.T. Lane, Department of Dermatology, Stanford University School of Medicine, Stanford, California, USA; H.I. Maibach, Department of Dermatology, University of California San Francisco, School of Medicine, San Francisco, California, USA; M. Wilkinson, Department of Dermatology, The General Infirmary at Leeds, Leeds, England; J.M. Wishart, Department of Dermatology, Auckland Hospital, Auckland, New Zealand.
Popper TL, Gentles MJ, Kung TT, et al. Structure-activity relationships of aseries of novel topical corticosteroids. J Steroid Biochem Mol Biol 1987; 27(4–6): 837–43
Gustafsson JA, Carlstedt-Duke J, Stromstedt PE, et al. Structure, function and regulation of the glucocorticoid receptor. Prog Clin Biol Res 1990; 322: 889–95
Flower RJ, Rothwell NJ. Lipocortin-lxellular mechanisms and clinical relevance. Trends Pharmacol Sci 1994; 15: 65–80CrossRef
Crocker IC, Zhou C-Y, Kreutner W, et al. Glucocorticoids inhibit leukotriene release by mixed leukocytes [abstract]. J Allergy Clin Immunol 1996; 97(Pt 3): 289CrossRef
Umland SP, Nahrebne DK, Razac S, et al. Effects of mometasone furoate and other glucocorticoids on cytokine production from cultured peripheral blood CD4+ T cells [abstract]. J Allergy Clin Immunol 1996; 97(Pt 3): 288CrossRef
Nissen JB, Kragballe K. Enkephalin levels in psoriatic skin after treatment with cacipotriol, mometasone furoate and heliobalneotherapy [abstract no. 349]. J Invest Dermatol 1997; 107: 462
Berti E, Richelda R, Bianchi B, et al. Evaluation of infiltrate cytokines receptors and adhesion molecules expression in psoriasis during topical treatment with mometasone furoate [abstract no. P-72]. In: American Academy of Dermatology: 1995 Annual Meeting Program supplement. New Orleans (LA), 1995
Bjerring P. Comparison of the bioactivity of mometasone furoate 0.1% fatty cream, betamethasone dipropionate 0.05% cream and betamethasone valerate 0.1% cream in humans-inhibition of UV-B-induced inflammation monitored by laser doppler blood flowmetry. Skin Pharmacol 1993; 6(3): 187–92PubMedCrossRef
Brannan MD, Seiberling M, Cutler DL, et al. Lack of systemic activity with intranasal mometasone furoate [abstract]. J Allergy Clin Immunol 1996; 97(Pt 3): 198CrossRef
Brannan MD, Herron JM, Reidenberg P, et al. Lack of HPA axis suppression following 36 days of intranasal mometasone furoate [abstract]. 1996 Annual Meeting of the American College of Allergy, Asthma and Immunology: 1996: 76
Bressinck R, Williams J, Peets E. Comparison of the effect of mometasone furoate ointment 0.1%, and hydrocortisone ointment 1%, on adrenocortical function in psoriasis patients. Today’S Ther Trends 1988; 5(4): 25–35
Higashi N, Katagiri K. Percutaneous absorption of 0.1% mometasone furoate ointment fate, excretion and adrenocortical suppression [in Japanese]. Skin Res 1990; 32(3): 395–402
Hadzija B W, Ambrose WW. Comparison of cosmetic and physicochemical properties of six topical corticosteroid creams. Cutis 1996 Feb; 57: 13–8PubMed
Hoybye A, Moller SB, De Cunha Bang F, et al. Continuous and intermittent treatment of atopic dermatitis in adults with mometasone furoate versus hydrocortisone 17-butyrate. Curr Ther Res 1991 Jul; 50: 67–72
Ishibashi Y, Harada S, Niimura M, et al. Long term topical application of 0.1% mometasone furoate ointment and cream. Studies on systemic effects, local adverse reactions and clinical effects [in Japanese] [English abstract]. Rinsho Iyaku 1990 Aug; 6: 1655–69
Rafanelli A, Rafanelli S, Stanganelli I, et al. Mometasone furoate in the treatment of atopic dermatitis in children. J Eur Acad Dermatol Venereol 1993; 2(3): 225–30CrossRef
Robertson DB, Maibach HI. Topical glucocorticoids. In: Schleimer RP, Claman HN, Oronsky A, editors. Anti-inflammatory steroid action. San Diego: Academic Press, 1989: 494–524
Cornell RC, Stoughton RB. The use of topical steroids in psoriasis. Dermatol Clin 1984; 2: 397–409
Stenmovic DU. Corticosteroid-induced atrophy of the skin with telangiectasia: a clinical and experimental study. Br J Dermatol 1972; 87: 548–56CrossRef
Hein R, Bosserhoff A, Wach F, et al. Effect of a newly synthesized glucocorticosteroid—mometasone furoate: on human keratinocytes and fibroblasts in vitro [abstract]. In: International Meeting Skin Therapy Update 94: 1994: 256
Kerscher MJ, Hart H, Korting HC, et al. In vivo assessment of the atrophogenic potency of mometasone furoate, a newly developed chlorinated potent topical glucocorticoid as compared to other topical glucocorticoids old and new. Int J Clin Pharmacol Ther 1995 Apr; 33: 187–9PubMed
Brasch J. The atrophogenic potential of mometasone furoate in a clinical long-term study [in German] [English abstract]. Z Hautkr 1991; 66(9): 785–7
Hoffman K, Auer T, Stucker M, et al. Skin atrophy and vasoconstriction with mometasone furoate compared with methylprednisolone and hydrocortisone. Schering-Plough Corporation Limited, data on file, November, 1997
Schering Corporation. Product information. Kenilworth (NJ): Schering Corporation, 1995. (Data on file)
Lebwohl M, Lane AT, Berman B, et al. Efficacy and safety of 0.1% mometasone furoate cream versus 0.2% hydrocortisone valerate cream in pediatric patients with atopic dermatitis unresponsive to topical hydrocortisone treatment [abstract no. P-43]. Proceedings of the 55th Annual Meeting of the American Academy of Dermatology: 1997 Mar 21–26: San Francisco
Bianchi B. Practical application of the SCORAD index in a clinical trial of children and adults with atopic dermatitis. Poster presentation in the 19th World Congress of Dermatology; 1997 Jun 15–20: Sydney
Giannetti A, Manzini BM, Bianchi B. Randomized, evaluation-blinded, multicenter study on onset of action, efficacy and safety of mometasone furoate 0.1% cream vs clobetasone butyrate 0.05% ointment in the treatment of atopic dermatitis [abstract no. P-229]. In: American Academy of Dermatology: 1995 Annual Meeting Program Supplement. New Orleans (LA), 1995
Marchesi E, Rozzoni M, Pini P, et al. Comparative study of mometasone furoate and betamethasone dipropionate in the treatment of atopic dermatitis. G Ital Dermatol Venereol 1994; 129(1–2): IX–XII
Reidhav I, Svensson Å. Betamethasone valerate versus mometasone furoate cream once daily in atopic dermatitis. J Dermatol Treat 1996 Jun; 7: 87–8CrossRef
Hersle K, Mobacken H, Nordin P. Mometasone furoate solution 0.1% compared with ketoconazole shampoo 2% for seborrheic dermatitis of the scalp. Curr Ther Res Clin Exp 1996 Jul; 57: 516–22CrossRef
Medansky RS, Lepaw MI, Shavin JS, et al. Mometasone furoate cream 0.1% vs. hydrocortisone cream 1% in the treatment of seborrhoeic dermatitis. J Dermatol Treat 1992 Sep; 3: 125–8CrossRef
Vanderploeg DE, Cornell RC, Binder R, et al. Clinical trial in scalp psorisis. Mometasone furoate 0.1% applied once daily vs betamethasone valerate lotion 0.1% applied twice daily. Acta Ther 1989 Apr; 15: 145–52
Svensson Å, Reidhav I, Gisslén H, et al. A comparative study of mometasone furoate ointment and betamethasone valerate ointment in patients with psoriasis vulgaris. Curr Ther Res 1992 Sep; 52: 390–6CrossRef
Medansky RS, Bressinck R, Cole GW, et al. Mometasone furoate ointment and cream 0.1 percent in treatment of psoriasis: comparison with ointment and cream formulations of fluocinolone acetonide 0.025 percent and triamcinolone acetonide 0.1 percent. Cutis 1988 Nov; 42: 480–5PubMed
Medansky RS, Brody NI, Kanof NB, et al. Clinical investigations of mometasone furoate—a novel nonfluorinated, topical corticosteroid. Semin Dermatol 1987; 6(2): 94–100
De Panfilis G, Braga D, Bianchi B. A randomised, multicentric, evaluator blinded study to compare mometasone furoate 0.1% ointment versus diflucortolone valerate 0.1% ointment in the treatment of psoriasis vulgaris [abstract no. P-111]. In: American Academy of Dermatology: 1995 Annual Meeting Program Supplement. New Orleans, LA, 1995
De Villez RL, Sher.AM, Breneman DL, et al. Comparison of the efficacy and safety of mometasone furoate ointment 0.1% once daily and fluticasone propionate ointment 0.005% twice daily in the management of psoriasis. Schering-Plough Corporation Limited, Kenilworth (NJ), 1997. (Data on file)
Santoro G, Fiallo P, Tagliapietra G, et al. Mometasone furoato a giorni alterni nel trattamento della psoriasi. G Ital Dermatol Venereol 1996; 131: 407–12
Bianchi B. Mometasone furoate and methylprednisolone aceponate in patients with contact dermatitis. Poster presentation in the 19th World Congress of Dermatology, Sydney, Australia, Jun 15–20, 1997
Dominguez L, Hojyo T, Vega E, et al. Comparison of the safety and efficacy of mometasone furoate cream 0.1% and clobetasone butyrate cream 0.05% in the treatment of children with a variety of dermatoses. Curr Ther Res 1990 Jul; 48: 128–39
Gip L, Lindberg L, Nordin P, et al. Clinical study of mometasone furoate cream 0.1% compared to hydrocortisone butyrate cream 0.1% in treatment of atopic and seborrheic dermatitis. Today’s Ther Trends 1990; 8(3): 21–34
Viglioglia P, Jones ML, Peets EA. Once-daily 0.1% mometasone furoate cream versus twice-daily 0.1% betamethasone valerate cream in the treatment of a variety of dermatoses. J Int Med Res 1990 Nov–Dec; 18: 460–7PubMed
Wishart JM, Lee I-S. Mometasone versus betamethasone creams: a trial in dermatoses. N Z Med J 1993 May 26; 106: 203–5PubMed
Rajka G, Avrach W, Gärtner L, et al. Mometasone furoate 0.1% fatty cream once daily versus betamethasone valerate 0.1% cream twice daily in the treatment of patients with atopic and allergic contact dermatitis. Curr Ther Res 1993 Jul; 54: 23–9CrossRef
Dooms-Goossens A, Lepoittevin J-R Studies on the contact allergenic potential of momethasone furoate: a clinical and molecular study. Eur J Dermatol 1996 Jul–Aug; 6: 339–40
Belsito DV. Allergic contact dermatitis to topical glucocorticosteroids. Cutis 1993; 52(5): 291–4PubMed
Finlay AY. Quality-of-life issues and economic burden of psoriasis and atopic dermatitis: rationale for treatment. Clin Drug Invest 1995; 10 Suppl. 1: 1–6CrossRef
Taylor B, Wadsworth J, Wadsworth M, et al. Changes in the reported prevalence of childhood eczema since the 1939–45 war. Lancet 1984; II: 1255–7CrossRef
Hsieh KH, Tsai YT. Increasing prevalence of childhood allergic disease in Taipei,Taiwan, and the outcome. In: Miyamoto T, Okuda M, editors. Progress in allergy and clinical immunology. Gottingen: Hogrefe & Huber, 1992: 223–5
Hogan PA. Atopic dermatitis. Patient Manage N Z 1997 Apr; 26: 35–43
Lebwohl M, Abel E, Zanolli M, et al. Topical therapy for psoriasis. Int J Dermatol 1995; 34(10): 673–84PubMed
Dutz JP, Ho VC. Immunosuppressive agents in skin disorders:a comparative review. Clin Ther 1996; 5(4): 268–93
- Topical Mometasone
Volume 55, Issue 1 , pp 145-163
- Cover Date
- Print ISSN
- Online ISSN
- Springer International Publishing
- Additional Links
- Industry Sectors